Neuroscience at a glance
Our long‐term commitment to advancing neuroscience and toxins research is evidenced by over 25 years of clinical experience. We are fully committed to improving people’s lives through safe and effective treatments, support and services in spasticity, movement disorders and specific indications in esthetic medicine.
At a glance
In 2018, our neuroscience division achieved sales of €347.8m, equivalent to 15.8% of our income.
We have over 25 years of experience in neurotoxins.
Our neuroscience team represents 21% of our Specialty Care business.
We have over 1000 employees dedicated to neuroscience.
In 2017, our ambition for neurotoxins was boosted by a £22 million investment at our campus at Wrexham, U.K.
We are the only company with recombinant toxins in our portfolio.
With a single product, DYSPORT®, we are able to treat a range of therapeutic indications including cervical dystonia, adult spasticity, hyperhidrosis, blepharospasm, hemifacial spasm and pediatric lower limb spasticity.
DYSPORT®, is authorized in more than 85 countries for seven therapeutic and two esthetic indications.
DYSPORT®, has 5 million treatment years of patient experience and is scientifically supported by over 1,300 peer‐reviewed publications.
We have a further 400 patents in our neuroscience division, most of which came from internal research activities.
Our partnership with Galderma, which has been extended until 2036, means that together we represent 75% of the world market for neurotoxins.
Through our 9 Ixcellence Network centers we have trained 728 physicians in the last five years.
Strategy and expertise
Our neuroscience pipeline
At our R&D centers around the world, and through numerous collaborative projects and partnerships with top academic institutes and investigators, we are pioneering research into neurotoxins. We have a leading-edge protein engineering expertise in toxins and we are pushing the boundaries of neurotoxin research to provide innovative therapeutic and aesthetic solutions to help patients take back control of their lives.
By participating in the tests and treatments outlined in a clinical trial, participants may gain a better understanding of different measurements and what they mean for health in the short-term and long-term.
Working with patients and healthcare providers
Ipsen has built strong, long-term partnerships with a number of patient associations and healthcare providers, including:
Dystonia Europe, an organization representing dystonia patients across the continent, and also with the American Dystonia Society. We continue to support initiatives for physicians who seek further research in cervical dystonia, disease awareness campaigns for patients and the creation of patient networks in Europe.
Ipsen’s I-CAN program is an innovative spasticity management program that engages patients in their own treatment.
Our long-running “Ixcellence Network” trains physicians in more than 20 countries and helps them set goals for self-guided rehabilitation. For esthetics practitioners, our educational masterclasses increase clinical and practical expertise for better outcomes
David Marsden’s Award
We are proud sponsors of the David Marsden’s Award which is presented every two years to encourage and drive research on dystonia, especially by young scientists in Europe.
Burden of Stroke in Europe
We sponsored the Burden of Stroke in Europe report, which was launched in the EU parliament in May 2017 and which highlighted disparities between countries along the stroke care pathway.
Our C.L.I.M.B.® (Continuum of Learning to Improve Management with Botulinum Toxin) programme is a multi‐tiered learning continuum designed to help physicians improve their clinical skills involving the appropriate use of DYSPORT® for the treatment of adults with cervical dystonia and spasticity.